Baseline and post-treatment results of categorical electrocardiographic variables in each study group. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Line graph showing the values of inflammatory cytokines at baseline and after treatment. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Baseline and Post-Treatment Myocardial Perfusion Defects Expressed as a Percentage of the Total Left Ventricular Surface Area in Each Experimental Group. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Baseline and post-treatment results of quantitative electrocardiographic variables in each study group. by Káryta Suely Macêdo Martins (22404155)

Subjects:

CONSORT diagram illustrating patient flow during the study. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Baseline and Post-Treatment Results of Echocardiographic Variables in Each Experimental Group. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Illustrative images of the processing of a myocardial perfusion study in a patient with Chagas disease. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Clinical and Demographic Characteristics of the Study Population. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Illustrative images of the quantitative processing of polar maps from a myocardial perfusion study in one of the investigated patients. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Baseline and Post-Treatment Serum Cytokine Levels in Each Investigational Group. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Baseline and Post-Treatment Serum Levels of NT-proBNP in Each Investigational Group. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Variables obtained from the SF-36 quality of life questionnaire in each experimental group. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Line graph showing the values of myocardial perfusion defects in the study groups. p = ANOVA Mixed Models. by Káryta Suely Macêdo Martins (22404155)

Subjects:

Decomposition analysis of the changes in prevalence (A), DALYs (B), and mortality (C) rates of IBD among women across global, 5 SDI and 21 GBD regions. by Jiefeng Zhao (9090305)

Subjects:

Health inequalities in the burden of IBD among WCBA. by Jiefeng Zhao (9090305)

Subjects:

Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021. by Jiefeng Zhao (9090305)

Subjects:

Estimated prevalence (A), DALYs (B), and mortality (C) rates of IBD in different age subgroups of WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

The global changes of prevalence (A-C), DALYs (D-F), and mortality (G-I) rates of IBD among WCBA from 1990 to 2021. by Jiefeng Zhao (9090305)

Subjects:

Frontier analysis for the potential for improvement in reducing the burden of IBD among WCBA across 204 countries and regions. by Jiefeng Zhao (9090305)

Subjects: